A 61-Year-Old Man With Acute Graft-Versus-Host Disease - Episode 5
Usama Gergis, MD: Let me comment on 2 very interesting trials with recently reported results. The REACH2 trial is a multicenter, phase 3 trial in patients with steroid-refractory acute graft-versus-host disease [GVHD] comparing ruxolitinib plus steroids versus best available treatment and steroids. Just like REACH1, the primary end point is overall response rate at day 28. The results of this very important trial were recently announced, and the trial reached the primary end point of overall response rate at day 28.
A paradox to this is the GRAVITAS-301 trial, which compared itacitinib, a JAK1 inhibitor in patients with chronic graft-versus-host disease versus placebo. The patients had chronic GVHD and were receiving itacitinib plus steroids versus placebo plus steroids, and there were no statistically significant responses. Let me take that back. There were no statistically significant differences in resolution of chronic graft-versus-host disease between the 2 arms or survival data. REACH2 is for [patients with] acute steroid-refractory [disease], and GRAVITAS-301 is for chronic GVHD. REACH2 is a blockbuster. GRAVITAS-301 is a bust.
Transcript edited for clarity.